Oisìn Biotechnologies: Raises $5M in Seed Funding

Oisìn Biotechnologies Raises $5M in Seed Funding

• Oisìn Biotechnologies, a Seattle WA-based company that specializes in mitigating the effects of age-related diseases, raised $5M in seed funding
• The round, which brought total funding to $9.5m, was led by Althea Group, LLC
• The company intends to use the funds for the preclinical development of its platform and investigational therapy for kidney and other age-related diseases
• Oisín is a late preclinical stage company developing therapeutics to reduce the effects of the aging process
• The company’s first therapies target senescent cells using its proprietary technology platform, SENSOlytics
• Its DNA-based interventions are designed to clear senescent cells, which can trigger aging pathologies and shorten lifespan, from the body